Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

Pembrolizumab is currently approved under the brand name Keytruda as a monotherapy and in combination regimens for patients with metastatic or with unresectable, recurrent HNSCC.

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...

The median PFS for pembrolizumab - the world's most popular cancer drug, sold by US pharmaceutical giant Merck under the brand name Keytruda - was 5.8 months by comparison, the study said.

The first Korean company granted Breakthrough Therapy Designation (BTD) from the U.S. FDA-Clinical trials and results from a three-year follow-up show significant improvements compared to existing ...

"Health Canada approves MSD’s Keytruda for NSCLC stages" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been ...

Keytruda, a PD-1 checkpoint inhibitor ... created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general ...

Fortive Corporation ("Fortive") today announced that James A. Lico, President and Chief Executive Officer, and Olumide Soroye, President and Chief Executive Officer of Intelligent Operating Solutions ...